187 related articles for article (PubMed ID: 34884730)
1. Substrate-Dependent
Lefèvre CR; Le Vée M; Gaubert S; Jouan E; Bruyere A; Moreau C; Fardel O
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884730
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Substrate-Dependent Ligand Interactions at the Organic Cation Transporter OCT2 Using Six Model Substrates.
Sandoval PJ; Zorn KM; Clark AM; Ekins S; Wright SH
Mol Pharmacol; 2018 Sep; 94(3):1057-1068. PubMed ID: 29884691
[TBL] [Abstract][Full Text] [Related]
3. Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates.
van der Velden M; Bilos A; van den Heuvel JJMW; Rijpma SR; Hurkmans EGE; Sauerwein RW; Russel FGM; Koenderink JB
Malar J; 2017 Oct; 16(1):422. PubMed ID: 29061131
[TBL] [Abstract][Full Text] [Related]
4. Investigations with Drugs and Pesticides Revealed New Species- and Substrate-Dependent Inhibition by Elacridar and Imazalil in
Kuehne A; Floerl S; Hagos Y
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555439
[TBL] [Abstract][Full Text] [Related]
5. Substrate-dependent ligand inhibition of the human organic cation transporter OCT2.
Belzer M; Morales M; Jagadish B; Mash EA; Wright SH
J Pharmacol Exp Ther; 2013 Aug; 346(2):300-10. PubMed ID: 23709117
[TBL] [Abstract][Full Text] [Related]
6. Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K.
Xiao G; Rowbottom C; Boiselle C; Gan LS
Pharm Res; 2018 Jun; 35(8):159. PubMed ID: 29915999
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporters 1 and 2.
Obianom ON; Coutinho AL; Yang W; Yang H; Xue F; Shu Y
Mol Pharm; 2017 Aug; 14(8):2726-2739. PubMed ID: 28699756
[TBL] [Abstract][Full Text] [Related]
8. Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates.
Hacker K; Maas R; Kornhuber J; Fromm MF; Zolk O
PLoS One; 2015; 10(9):e0136451. PubMed ID: 26327616
[TBL] [Abstract][Full Text] [Related]
9. Effect of 7-ketocholesterol incorporation on substrate binding affinity and turnover rate of the organic cation transporter 2 (OCT2).
Xiu F; Console L; Indiveri C; Su S; Wang T; Visentin M
Biochem Pharmacol; 2024 Feb; 220():116017. PubMed ID: 38176620
[TBL] [Abstract][Full Text] [Related]
10. Fluorocholine Transport Mediated by the Organic Cation Transporter 2 (OCT2, SLC22A2): Implication for Imaging of Kidney Tumors.
Visentin M; Torozi A; Gai Z; Häusler S; Li C; Hiller C; Schraml PH; Moch H; Kullak-Ublick GA
Drug Metab Dispos; 2018 Aug; 46(8):1129-1136. PubMed ID: 29794161
[TBL] [Abstract][Full Text] [Related]
11. Differential
Bruyère A; Le Vée M; Jouan E; Molez S; Nies AT; Fardel O
Xenobiotica; 2021 Apr; 51(4):467-478. PubMed ID: 33455503
[TBL] [Abstract][Full Text] [Related]
12. Plasma Membrane Cholesterol Regulates the Allosteric Binding of 1-Methyl-4-Phenylpyridinium to Organic Cation Transporter 2 (SLC22A2).
Hörmann S; Gai Z; Kullak-Ublick GA; Visentin M
J Pharmacol Exp Ther; 2020 Jan; 372(1):46-53. PubMed ID: 31624079
[TBL] [Abstract][Full Text] [Related]
13. Kinetic basis of metformin-MPP interactions with organic cation transporter OCT2.
Sandoval PJ; Morales M; Secomb TW; Wright SH
Am J Physiol Renal Physiol; 2019 Sep; 317(3):F720-F734. PubMed ID: 31313952
[TBL] [Abstract][Full Text] [Related]
14. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
[TBL] [Abstract][Full Text] [Related]
15. Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition.
Müller F; Weitz D; Mertsch K; König J; Fromm MF
Mol Pharm; 2018 Aug; 15(8):3425-3433. PubMed ID: 29975542
[TBL] [Abstract][Full Text] [Related]
16. Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220.
Mayati A; Bruyere A; Moreau A; Jouan E; Denizot C; Parmentier Y; Fardel O
PLoS One; 2015; 10(12):e0144667. PubMed ID: 26657401
[TBL] [Abstract][Full Text] [Related]
17. Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.
Meyer MJ; Seitz T; Brockmöller J; Tzvetkov MV
PLoS One; 2017; 12(12):e0189521. PubMed ID: 29236753
[TBL] [Abstract][Full Text] [Related]
18. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
[TBL] [Abstract][Full Text] [Related]
19. 3D-QSAR analysis of the interactions of flavonoids with human organic cation transporter 2.
Bi Y; Wang X; Li H; Tian Y; Han L; Gui C; Zhang Y
Toxicol Lett; 2022 Sep; 368():1-8. PubMed ID: 35901987
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2).
Zhu P; Ye Z; Guo D; Xiong Z; Huang S; Guo J; Zhang W; Polli JE; Zhou H; Li Q; Shu Y
Pharm Res; 2018 Oct; 35(12):243. PubMed ID: 30361780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
